PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
PharmaTher Expands PharmaPatch Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
PharmaTher Applauds FDA's Commissioner's National Priority Voucher Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505 Focus, and Upside from Strategic ANDA Sale
PharmaTher Announces KetAImine - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505 NDA Filings
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine ), Aligned with FDA's CNPV National Priority Initiative
